僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Tusamitamab ravtansine （SAR-408701） is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 （HY-12454）, via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio （DAR） of 3.8